W. Roche (Southampton, United Kingdom), E. Danila (Vilnius, Lithuania)
MDM2 gene amplification and mdm2 protein expression in NSCLC cells D. Dworakowska, E. Jassem, J. Jassem, R. Schneider-Stock, C. Boltze, K. H. Wiedorn, J. Skokowski, K. Jaskiewicz, E. Czestochowska (Gdansk, Poland; Magdeburg, Stuttgart, Germany)
| |
Local clustering of lung carcinoid tumors (LCTs) in a small area of central Greece: genetic abnormalities involving multiple endocrine neoplasia 1 (MEN1) gene on chromosome 11q Z. Daniil, D. Vageli, A. Koutsokera, D. Papadopoulos, J. Dahabreh, E. Karagianni, M. Ioannou, K. Gourgoulianis (Larissa, Athens, Greece)
| |
Thrombin activatable fibrinolytic inhibitor in sera from NSCLC patients D. Dworakowska, A. Kulwas, M. Lapinski, D. Tomaszewski, R. Dworakowski, J. Skokowski, E. Zekanowska, D. Rosc, E. Czestochowska (Gdansk, Bydgoszcz, Poland)
| |
Alteration in subpopulations of peripheral T lymphocytes in squamous cell lung cancer D. Dworakowska, E. Bryl, M. Soroczynska, J. M. Witkowski, M. Lapinski, D. Tomaszewski, R. Dworakowski, J. Skokowski, E. Czestochowska (Gdansk, Poland)
| |
Tumour infiltrating lymphocytes and tumour associated macrophages in chronic obstructive pulmonary disease (COPD) patients with non-small cell lung cancer (NSCLC) and in patients with NSCLC P. Boschetto, N. Lo Cascio, D. Miotto, L. Mazzetti, E. Zeni, M. Pedriali, P. Querzoli, S. Chiarelli, E. De Rosa, L. M. Fabbri, C. E. Mapp (Ferrara, Padova, Modena, Italy)
| |
Significant correlation between interleukin-10 expression and progression of non-small cell lung cancer through heme oxygenase P. Boschetto, E. Zeni, L. Mazzetti, P. Maestrelli, B. Murer, P. Querzoli, M. Pedriali, D. Miotto, E. De Rosa, L. M. Fabbri, C. E. Mapp (Ferrara, Padova, Mestre, Modena, Italy)
| |
Time course of exhaled hydrogen peroxide (H2O2) and nitric oxide (eNO) during chemotherapy in patients with lung cancer A. R. Wewel, J. A. Crusius, U. Gatzemeier, G. Becher, H. Magnussen, R. A. Jörres, O. Holz (Großhansdorf, Munich, Berlin, Germany)
| |
Benzamidine-type urokinase inhibitors reduce primary tumor growth in a Lewis lung carcinoma model C. Ruppert, I. Henneke, P. Markart, S. Greschus, J. Stürzebecher, W. Seeger, A. Günther (Giessen, Jena, Germany)
| |
Arg72Pro and GSTM1 gene polymorphisms increase the risk of non small cell lung cancer (NSCLC) A. Szymanowska, E. Jassem, A. Borg, K. Holm, M. Perkowska, R. Dziadziuszko, W. Rzyman, G. Kobierska-Gulida, J. Limon, J. Jassem (Gdansk, Poland; Lund, Sweden)
| |
Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients M. Skrzypski, A. Szymanowska, E. Jassem, J. Niklinski, R. Dziadziuszko, G. Gulida, W. Rzyman, J. Limon, J. Jassem (Gdansk, Bialystok, Poland)
| |
Mutation of TP53 and KRAS, and loss of p16ink4a and p14arf expression in lung cancers in relation to tobacco smoke F. Le Calvez, A. Mukeria, J. D. Hunt, O. Kelm, R. J. Hung, P. Taniere, P. Brennan, P. Boffetta, D. G. Zaridze, P. Hainaut, E. Brambilla (Lyon, Grenoble, France; Moscow, Russian Federation; New Orleans, USA; Birmingham, UK)
| |
The mechanism of plasminogen activator inhibitor type-1 (PAI-1) Cys mutants inhibitory activity towards lung capillaries endothelial cells (HMVEC-L) J. Chorostowska-Wynimko, E. Skrzypczak-Jankun, S. Selman, J. Jankun (Warsaw, Poland; Toledo, United States Of America)
| |
Morphological changes of respiratory muscles in patients with lung cancer P. S. Irina, L. G. Boris (St. Petersburg, Russian Federation)
| |
Gene expression profiling of lung adenocarcinoma by microarray analysis Y. M. Rosmadi, S. M. Mohamed-Saifulaman, H. Roslan (Kuala Lumpur, Malaysia)
| |
Cytosolic phospholipase A2 promoter repeats polymorphisms regulate its transcriptional activity R. Pawliczak, M. Sokolowska, A. M. Lewandowicz, M. Kowalski (Lodz, Poland)
| |